Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30849549 | 1.00 | P2RX7 (0.37) | P2RX7IDO1AGXTNR3C2KDM4C | |
| SCHEMBL6002267 | 0.86 | MAPT (0.35) | P2RX7NR3C2KDM4CKDM5AKDM5B | |
| SCHEMBL11116185 | 0.82 | SLC6A4 (0.39) | P2RX7ACHEPTGS1PTGS2 | |
| SCHEMBL7901204 | 0.79 | P2RX7 (0.41) | P2RX7IDO1AGXTNR3C2MMP1 | |
| SCHEMBL28056457 | 0.78 | IDO1 (0.40) | IDO1AGXTCYP1A2SMN1; SMN2 | |
| SCHEMBL14533298 | 0.77 | P2RX7 (0.37) | P2RX7IDO1AGXTNR3C2KDM4C | |
| SCHEMBL13787148 | 0.77 | IDO1 (0.41) | P2RX7IDO1AGXTNR3C2KDM4C | |
| SCHEMBL1371586 | 0.77 | P2RX7 (0.37) | P2RX7IDO1AGXTNR3C2MMP1 | |
| SCHEMBL2476555 | 0.77 | MAPK14 (0.40) | P2RX7IDO1AGXTNR3C2KDM4C | |
| SCHEMBL2475943 | 0.77 | MPO (0.44) | P2RX7IDO1AGXTNR3C2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| EP-3854789-A1 | MACROCYCLIC COMPOUNDS USEFUL AS CHITINASE INHIBITORS | CYGNET BIOSCIENCES B.V. (CW) | 2021-07-28 | — | — | EP | disclosed |
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3619200-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| CN-110770214-A | Heterocyclic P2X7 antagonists | 阿克萨姆股份公司 | 2020-02-07 | — | — | CN | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| CN-1805957-A | Azetidine compounds | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | CN | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| EP-0034415-B1 | 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-05-30 | — | — | EP | disclosed |
| US-4369184-A | ANTIHISTAMINES; HETEROCYCLIC NITRILES | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-18 | — | — | US | disclosed |
| EP-0034415-A1 | 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | P2RX7 2751/4885IDO1 2403/4885AGXT 1515/4885 |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | P2RX7 4/4885IDO1 1048/4885AGXT 2029/4885 |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | P2RX7 4/4885IDO1 1048/4885AGXT 2029/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | P2RX7 2751/4885IDO1 2403/4885AGXT 1515/4885 |
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | P2RX7 330/4885IDO1 268/4885AGXT 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.